Compare · NDRA vs SLNO
NDRA vs SLNO
Side-by-side comparison of ENDRA Life Sciences Inc. (NDRA) and Soleno Therapeutics Inc. (SLNO): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both NDRA and SLNO operate in Biotechnology: Electromedical & Electrotherapeutic Apparatus (Health Care), so they compete in similar markets.
- SLNO is the larger of the two at $2.76B, about 458.2x NDRA ($6.0M).
- Over the past year, NDRA is down 9.9% and SLNO is down 37.9% - NDRA leads by 28.0 points.
- NDRA has hit the wire 3 times in the past 4 weeks while SLNO has been quiet.
- SLNO has more recent analyst coverage (12 ratings vs 0 for NDRA).
- Company
- ENDRA Life Sciences Inc.
- Soleno Therapeutics Inc.
- Price
- $5.74+8.92%
- $53.02+0.08%
- Market cap
- $6.0M
- $2.76B
- 1M return
- -7.12%
- +0.76%
- 1Y return
- -9.89%
- -37.87%
- Industry
- Biotechnology: Electromedical & Electrotherapeutic Apparatus
- Biotechnology: Electromedical & Electrotherapeutic Apparatus
- Exchange
- NASDAQ
- NASDAQ
- IPO
- 2017
- 2014
- News (4w)
- 3
- 0
- Recent ratings
- 0
- 12
ENDRA Life Sciences Inc.
ENDRA Life Sciences Inc. develops technology for clinical diagnostic ultrasound. It develops thermo-acoustic enhanced ultrasound technology that transmits sound waves, which bounce off tissues, organs, and blood for the treatment of nonalcoholic fatty liver disease, as well as temperature monitoring of thermoablative surgery, vascular imaging, and tissue perfusion. The company also offers diagnostic imaging technologies, such as computed tomography, magnetic resonance imaging, and ultrasound that allow physicians to look inside a person's body to guide treatment or gather information about medical conditions, such as broken bones, cancers, signs of heart disease, or internal bleeding. The company has a collaborative research agreement with General Electric Company. ENDRA Life Sciences Inc. was incorporated in 2007 and is based in Ann Arbor, Michigan.
Soleno Therapeutics Inc.
Soleno Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutics for the treatment of rare diseases. Its lead candidate is Diazoxide Choline Controlled-Release (DCCR), a once-daily oral tablet for the treatment of Prader-Willi Syndrome (PWS), is being evaluated in a Phase III clinical development program. The company was formerly known as Capnia, Inc. and changed its name to Soleno Therapeutics, Inc. in May 2017. Soleno Therapeutics has collaboration with Vanderbilt University to discover and develop next generation K(ATP) channel activators for the treatment of rare diseases. Soleno Therapeutics, Inc. was incorporated in 1999 and is headquartered in Redwood City, California.
Latest NDRA
- SEC Form 425 filed by ENDRA Life Sciences Inc.
- Join the Live Investor Webinar for Noble Africa, the Proposed ASP Isotopes Spin-Out Creating a Public Helium Company
- ENDRA Life Sciences Inc. filed SEC Form 8-K: Other Events
- Amendment: SEC Form SCHEDULE 13D/A filed by ENDRA Life Sciences Inc.
- SEC Form 425 filed by ENDRA Life Sciences Inc.
- ENDRA Life Sciences Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Changes in Control of Registrant, Regulation FD Disclosure, Other Events, Financial Statements and Exhibits
- SEC Form 144 filed by ENDRA Life Sciences Inc.
- SEC Form 425 filed by ENDRA Life Sciences Inc.
- ENDRA Life Sciences Inc. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits
- ENDRA Life Sciences Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities, Other Events, Financial Statements and Exhibits
Latest SLNO
- Palvella Therapeutics Appoints Accomplished Rare Disease Biotech Executive and Commercial Leader Matt Pauls, J.D., M.B.A., to Board of Directors
- SEC Form 15-12G filed by Soleno Therapeutics Inc.
- SEC Form EFFECT filed by Soleno Therapeutics Inc.
- SEC Form POS AM filed by Soleno Therapeutics Inc.
- SEC Form AW filed by Soleno Therapeutics Inc.
- Officer Yen Kristen returned 37,639 shares to the company, closing all direct ownership in the company (SEC Form 4)
- Director Volck Birgitte returned 17,536 shares to the company, closing all direct ownership in the company (SEC Form 4)
- Director Sinclair Andrew returned 10,491 shares to the company, closing all direct ownership in the company (SEC Form 4)
- Director Pauls Matthew returned 10,491 shares to the company, closing all direct ownership in the company (SEC Form 4)
- Chief Business Officer Norrett Kevin returned 17,786 shares to the company, closing all direct ownership in the company (SEC Form 4)